Security key
84833T103
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)
CUSIP: 84833T103
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 11,078,704
- Total 13F value
- $32,127,617
- Share change
- -4,029,340
- SEC-reported price per share
- $2.90
- Number of holders
- 44
- Value change
- -$7,947,299
- Number of buys
- 24
- Number of sells
- 19
- Shares outstanding
- 55,705,828
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
44
Top holders
10
SPRO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Spero Therapeutics, Inc. SEC filings
Spero Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 84833T103
Recent filing periods:
Ownership snapshot
Top reported holders of SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GSK plc
Disclosed value leader
GSK plc
Comparable rows
2/15
Latest evidence
30 Jun 2025
3/4/5
13D/G
13F
Lead comparable stake: 16%
13 rows are not safely comparable across share classes.
13D/G row: GSK plc
Showing 1-6 of 15 holder rows.
Quick read
GSK plc leads the comparable SEC ownership view at 16%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GSK plc's linked filing trail.
Comparable ownership
Top 2
GSK plc
16%
Anson Funds Management LP
2.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GSK plc |
3/4/5
13D/G
10%+ Owner
|
16%
Reported 13D/G
· 27 Mar 2025
|
$11,672,070
9,190,606 shares
|
— | 07 Nov 2022 |
| Anson Funds Management LP |
13D/G
13F
Company
|
2.9%
Reported 13D/G
· 30 Jun 2025
|
$4,587,932
1,615,469 shares
|
$0 | 30 Jun 2025 |
| Aquilo Capital Management, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$4,342,682
3,419,435 shares
|
— | 22 Sep 2022 |
| PFIZER INC |
13F
Company
|
—
denominator unverified
|
$1,700,891
2,362,348 shares
|
— | 31 Mar 2025 |
| Sath Shukla |
3/4/5
CEO & President
|
—
denominator unverified
|
$1,354,769
1,736,883 shares
|
— | 03 Feb 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$1,269,807
1,763,620 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
44
Shares
11,078,704
Rows available
44
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
38
Q2 2025 holders
44
Holder diff
6
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend